SCHEDULE 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

8-K/A - Verve Therapeutics, Inc. (0001840574) (Filer)

8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development candidate targeting the LPA gene; Verve to receive an associated milestone payment from Eli Lilly Well-capitalized with cash runway extending into mid-2027 Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. ET/11:15 a.m. PT BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) --  Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 30 days following the presentation. About Verve Therapeutics Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovas

BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024, the company granted equity awards to one new employee, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee's continued service with the company

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee's continued service with the company

Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3; Regulatory clearances in Australia, Canada, and the U.K. Cash, cash equivalents, and marketable securities of $539.9 million; cash runway through 2026 BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today reported pipeline updates and financial results for the quarter ended September 30, 2024. "In the third quarter, we made c

BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024, the company granted equity awards to six new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 47,600 shares of the company's common stock and an aggregate of 42,710 restricted stock units (RSUs). The options have an exercise price of $5.73 per share, which is eq

BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30, 2024, the company granted equity awards to five new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received an aggregate of 33,280 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to each such employee's continued service with t

BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024, the company granted equity awards to two new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received an aggregate of 12,600 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to each such employee's continued service with the

Heart-2 clinical trial of VERVE-102 enrolling in the U.K. and Canada; Clinical Trial Application cleared in Australia Heart-2 and PCSK9 program data update planned for first half of 2025 Phase 1b clinical trial initiation for VERVE-201 on track for the second half of 2024 Cash, cash equivalents, and marketable securities of $575.9 million; cash runway into late 2026 BOSTON , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today reported pipeline updates and financial results for the quarter ended June 30, 2024. "The second quarter has been a period of continued execution fo

BOSTON, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on July 31, 2024, the company granted equity awards to five new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 91,200 shares of the company's common stock and an aggregate of 37,300 restricted stock units (RSUs). The options have an exercise price of $7.00 per share, which is equal t

4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (NASDAQ:VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations. "Allison joins Verve at an exciting stage of our company's evolution, on the heels of a successful IPO earlier this year and recent preclinical data updates from our lead programs targeting PCSK9 and ANGPTL3 as base editing

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear

H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00

Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00

Cantor Fitzgerald initiated coverage of Verve Therapeutics with a rating of Neutral and set a new price target of $21.00

Goldman initiated coverage of Verve Therapeutics with a rating of Sell and set a new price target of $13.00

Credit Suisse initiated coverage of Verve Therapeutics with a rating of Neutral and set a new price target of $48.00

Stifel upgraded Verve Therapeutics from Hold to Buy and set a new price target of $56.00 from $32.00 previously

BMO Capital Markets initiated coverage of Verve Therapeutics with a rating of Outperform and set a new price target of $48.00

RBC Capital initiated coverage of Verve Therapeutics with a rating of Outperform and set a new price target of $42.00

Stifel initiated coverage of Verve Therapeutics with a rating of Hold and set a new price target of $58.00

Jefferies initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $72.00